Lescol Xl
Product Images NDC 54868-4601

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lescol Xl (NDC 54868-4601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 80 mg Package Label (4601)

Label for LESCOL XL 80MG tablets distributed by Physicians Total Care, Inc. The label indicates a package of 30 tablets with NDC 54868-4601-0. It includes lot number 0000 and an expiration date of 01/60, with manufacturing attribution to Novartis Pharmaceuticals Corp., Suffern, NY 10901. A barcode is present at the bottom of the label.*

FDA Label Image

Image Of Chemcial Structure (Lescol 02)

Chemical structure diagram of the active ingredient in LESCOL XL, showing a fluorophenyl group, hydroxyl groups, and molecular formula C24H25FNO4·Na with a molecular weight of 433.46.*

FDA Label Image

Image Of Figure 1 Graph (Lescol 03)

A Kaplan-Meier survival curve comparing the percentage of patients without events over time between Fluvastatin 80 mg and Placebo groups. The x-axis represents years since randomization up to 4.5 years, and the y-axis shows the percentage of patients without events from 0 to 100%. The graph includes statistics with p-values and hazard ratio, indicating a comparison of event-free survival between treatments.*

FDA Label Image

Image Of Figure 2 Chart (Lescol 04)

A forest plot chart showing comparative incidence rates and risk reduction percentages with 95% confidence intervals for primary and secondary cardiovascular events in the LESCOL XL versus placebo groups. The plot includes event categories such as cardiac death, nonfatal MI, and revascularization, with Cox risk ratios and confidence intervals visually displayed using horizontal lines and squares on the plot's scale, indicating favorability towards Lescol XL or placebo.*

FDA Label Image

Image Of Figure 3 Chart (Lescol 05)

A bar chart titled "Change in Minimum Lumen Diameter (mm)" comparing several treatment groups including Lescol® F=Placebo and Lescol® Placebo across subgroups: Miderartery, All Patients, and Lescol Combined with CEE vs Placebo. The y-axis measures minimum lumen diameter change in millimeters, ranging from positive to negative values.*

FDA Label Image

Image Of Figure 4 Chart (Lescol 06)

A bar chart titled 'Charge in % Diameter Stenosis' comparing Lescol XL and placebo groups in three categories: Microsurgery, All Patients, and Lescol XL plus Rosuvastatin/Colestipol. The chart shows percentage changes with statistical significance (p-values) indicated above bars, illustrating efficacy measurements related to diameter stenosis change.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.